GlassScriptPhysician profile
Rekha Sehgal
NPI 1629019955
$7,742.41
in general payments reported to CMS, 2019-2025
42 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $671 · 2021: $720 · 2022: $1,251 · 2023: $1,444 · 2024: $1,064 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,810.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,291.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,014.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $726.70 | 2019-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $635.39 | 2022-2025 | |
| Pfizer INC. | $389.26 | 2019-2025 | |
| Lilly USA, LLC | $348.53 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $346.59 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $275.40 | 2020-2025 | Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.51 | 2021-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $210.76 | 2022 | |
| Amarin Pharma, INC. | $186.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.61 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $175.10 | 2020-2025 | |
| Integrity Implants INC. Dba Accelus | $156.98 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $138.95 | 2019-2024 | Austedo Xr |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $125.50 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Kowa Pharmaceuticals America, INC. | $121.52 | 2022-2023 | Livalo, Seglentis |
| Insmed, INC. | $117.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $100.25 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $99.24 | 2019 | |
| Exact Sciences Corporation | $81.60 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $81.27 | 2023-2025 | Rexulti |
| Boston Scientific Corporation | $80.03 | 2019 | |
| Astellas Pharma US INC | $69.58 | 2019-2023 | Myrbetriq |
| Insulet Corporation | $67.02 | 2024-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $64.17 | 2019-2022 | |
| Daiichi Sankyo INC. | $63.38 | 2022-2023 | Injectafer |
| Medtronic, INC. | $50.95 | 2023-2025 | Minimed 780g, Minimed 770g |
| Abbott Laboratories | $45.04 | 2021-2022 | |
| Dexcom, INC. | $29.84 | 2021 | |
| Neurocrine Biosciences, INC. | $29.03 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.18 | 2024 | Voquezna |
| Seqirus USA INC | $25.74 | 2019-2020 | |
| Ucb, INC. | $18.40 | 2025 | Briviact |
| Sanofi Pasteur INC. | $16.08 | 2023 | |
| Philips North America LLC | $15.69 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.37 | 2025 | Nuzyra |
| Shield Therapeutics INC | $14.27 | 2023 | Accrufer |
| Allergan, INC. | $13.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.38 | 2020 | |
| Eisai INC. | $13.10 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rekha Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.